AU2008334941B2 - Advantageous salts of mu-opiate receptor peptides - Google Patents

Advantageous salts of mu-opiate receptor peptides Download PDF

Info

Publication number
AU2008334941B2
AU2008334941B2 AU2008334941A AU2008334941A AU2008334941B2 AU 2008334941 B2 AU2008334941 B2 AU 2008334941B2 AU 2008334941 A AU2008334941 A AU 2008334941A AU 2008334941 A AU2008334941 A AU 2008334941A AU 2008334941 B2 AU2008334941 B2 AU 2008334941B2
Authority
AU
Australia
Prior art keywords
salt
salts
hydrochloride
sample
scaled
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2008334941A
Other languages
English (en)
Other versions
AU2008334941A1 (en
Inventor
Theodore E. Maione
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytogel Pharma LLC
Original Assignee
Cytogel Pharma LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytogel Pharma LLC filed Critical Cytogel Pharma LLC
Publication of AU2008334941A1 publication Critical patent/AU2008334941A1/en
Assigned to CYTOGEL, LLC reassignment CYTOGEL, LLC Amend patent request/document other than specification (104) Assignors: CYTOGEL PHARMA, LLC
Application granted granted Critical
Publication of AU2008334941B2 publication Critical patent/AU2008334941B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AU2008334941A 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides Ceased AU2008334941B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US761707P 2007-12-13 2007-12-13
US61/007,617 2007-12-13
PCT/US2008/086838 WO2009076672A1 (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Publications (2)

Publication Number Publication Date
AU2008334941A1 AU2008334941A1 (en) 2009-06-18
AU2008334941B2 true AU2008334941B2 (en) 2013-02-14

Family

ID=40755912

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2008334941A Ceased AU2008334941B2 (en) 2007-12-13 2008-12-15 Advantageous salts of mu-opiate receptor peptides

Country Status (7)

Country Link
US (6) US20110190214A1 (enExample)
EP (2) EP2826786B1 (enExample)
JP (1) JP5647002B2 (enExample)
AU (1) AU2008334941B2 (enExample)
CA (2) CA2984218C (enExample)
ES (1) ES2550604T3 (enExample)
WO (1) WO2009076672A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110065648A1 (en) * 2009-09-15 2011-03-17 Maione Theodore E Advantageous mu-opiate receptor peptide compounds
EP2574172A4 (en) * 2010-05-21 2013-10-30 Cytogel Pharma Llc MATERIALS AND METHOD FOR TREATING INFLAMMATION
WO2013173730A2 (en) * 2012-05-18 2013-11-21 Cytogel Pharma, Llc. Novel therapeutic uses of mu-opiate receptor peptides
CN110769843A (zh) * 2017-06-12 2020-02-07 内布拉斯加大学董事会 C5a受体激动剂肽的盐酸盐
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111511757A (zh) * 2017-11-17 2020-08-07 细胞凝胶制药有限责任公司 μ阿片受体的聚合物激动剂

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042732A1 (en) * 1997-03-25 1998-10-01 The Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235496B1 (en) * 1993-03-08 2001-05-22 Advanced Research & Technology Institute Nucleic acid encoding mammalian mu opioid receptor
US5942492A (en) * 1996-11-12 1999-08-24 Angstrom Pharmaceuticals, Inc. Cyclic peptides that bind to urokinase-type plasminogen activator receptor
JPH10330398A (ja) * 1997-05-28 1998-12-15 Asahi Glass Co Ltd 新規環状ペプチド
SE9800865D0 (sv) * 1998-03-16 1998-03-16 Astra Ab New Process
JPWO2002102833A1 (ja) * 2001-06-15 2004-09-30 千寿製薬株式会社 新規エンドモルフィン誘導体
EP1427438A2 (en) 2001-09-03 2004-06-16 The University of Bristol Inflammation modulatory compound comprising an endomorphin
WO2003066593A2 (en) * 2001-11-29 2003-08-14 Schering Corporation Preparation of pharmaceutical salts of 4 ( (z) - (4-bromophenyl) (ethoxyimino) methyl )-1'-( (2,4-dimethyl-1-oxido-3-pyridinyl) carbonyl) -4'-methyl-1,4' bipiperidine as ccr5-antagonists for the treatment of aids and related hiv infections

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042732A1 (en) * 1997-03-25 1998-10-01 The Administrators Of The Tulane Educational Fund Mu-opiate receptor peptides

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CARDILLO, G. et al. J. Med. Chem. (2002), 45(9), 2571-2578 *
CARDILLO, G. et al. Org. Biomol. Chem. (2003), 1, 1498-1502 *

Also Published As

Publication number Publication date
EP2826786B1 (en) 2015-09-23
EP2826786A1 (en) 2015-01-21
ES2550604T3 (es) 2015-11-11
JP2011508727A (ja) 2011-03-17
US20150152137A1 (en) 2015-06-04
CA2707733C (en) 2018-01-02
US20220324908A1 (en) 2022-10-13
EP2229400A1 (en) 2010-09-22
EP2229400B1 (en) 2014-11-19
US20180291060A1 (en) 2018-10-11
US20200339628A1 (en) 2020-10-29
US8940704B2 (en) 2015-01-27
CA2984218C (en) 2019-12-31
WO2009076672A1 (en) 2009-06-18
EP2229400A4 (en) 2012-01-04
HK1206363A1 (en) 2016-01-08
AU2008334941A1 (en) 2009-06-18
US20140142050A1 (en) 2014-05-22
JP5647002B2 (ja) 2014-12-24
CA2984218A1 (en) 2009-06-18
US20110190214A1 (en) 2011-08-04
CA2707733A1 (en) 2009-06-18

Similar Documents

Publication Publication Date Title
US20220324908A1 (en) Advantageous salts of mu-opiate receptor peptides
US6242460B1 (en) Zolpidem salt forms
JP2021530456A (ja) ２−（３，５−ジクロロ−４−（（５−イソプロピル−６−オキソ−１，６−ジヒドロピリダジン−３−イル）オキシ）フェニル）−３，５−ジオキソ−２，３，４，５−テトラヒドロ−１，２，４−トリアジン−６−カルボニトリルの固体形態
US8293704B2 (en) Crystalline form of linaclotide
US8946474B2 (en) Polymorphic form of a calcimimetic compound
US12559478B2 (en) Co-crystal forms of selinexor
US11136332B2 (en) Morphic forms of marizomib and uses thereof
HK1206363B (en) Advantageous salts of mu-opiate receptor peptides
CA3112986C (en) Erbumine salt of treprostinil
WO2000058310A1 (en) Zolpidem salts
WO2007070563A2 (en) Stable solid forms of enterostatin
US12448347B2 (en) Polymorphic forms of (R)-oxybutynin hydrochloride
WO2025231285A1 (en) Peptide analogs and methods of using the same
US20210032235A1 (en) Crystalline forms of dasatinib
CN102958907A (zh) 钙敏感受体激动化合物的新多晶型

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired